Trial · NCT01332318
Results by group425
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 425
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax) | GEn Placebo and DPH Placebo | -0.10 | Standard Error 0.06 | feet | |
| Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax) | GEn 1200 mg and DPH Placebo | 0.15 | Standard Error 0.06 | feet | |
| Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax) | GEn 1800 mg and DPH Placebo | 0.15 | Standard Error 0.06 | feet | |
| Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax) | GEn Placebo and DPH 50 mg on Day 16 | 0.16 | Standard Error 0.06 | feet | |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn Placebo and DPH Placebo | Day 14, n=33, 28, 33, 28 | -0.06 | Standard Deviation 0.17 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn 1200 mg and DPH Placebo | Day 14, n=33, 28, 33, 28 | 0.17 | Standard Deviation 0.43 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn 1800 mg and DPH Placebo | Day 14, n=33, 28, 33, 28 | -0.01 | Standard Deviation 0.28 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn Placebo and DPH 50 mg on Day 16 | Day 14, n=33, 28, 33, 28 | -0.08 | Standard Deviation 0.15 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn Placebo and DPH Placebo | Day 15, n=32, 28, 31, 27 | -0.01 | Standard Deviation 0.14 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn 1200 mg and DPH Placebo | Day 15, n=32, 28, 31, 27 | 0.13 | Standard Deviation 0.40 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn 1800 mg and DPH Placebo | Day 15, n=32, 28, 31, 27 | 0.02 | Standard Deviation 0.32 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV) | GEn Placebo and DPH 50 mg on Day 16 | Day 15, n=32, 28, 31, 27 | -0.10 | Standard Deviation 0.19 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn Placebo and DPH Placebo | Day 14, n=33, 28, 33, 28 | 0.05 | Standard Deviation 0.35 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn 1200 mg and DPH Placebo | Day 14, n=33, 28, 33, 28 | -0.02 | Standard Deviation 0.64 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn 1800 mg and DPH Placebo | Day 14, n=33, 28, 33, 28 | 0.03 | Standard Deviation 0.32 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn Placebo and DPH 50 mg on Day 16 | Day 14, n=33, 28, 33, 28 | 0.08 | Standard Deviation 0.29 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn Placebo and DPH Placebo | Day 15, n=32, 28, 31, 27 | 0.01 | Standard Deviation 0.35 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn 1200 mg and DPH Placebo | Day 15, n=32, 28, 31, 27 | 0.12 | Standard Deviation 0.39 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn 1800 mg and DPH Placebo | Day 15, n=32, 28, 31, 27 | 0.04 | Standard Deviation 0.34 | feet |
| Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position | GEn Placebo and DPH 50 mg on Day 16 | Day 15, n=32, 28, 31, 27 | 0.04 | Standard Deviation 0.28 | feet |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01332318/results